Ipilimumab Feasible for Patients Who Relapse After Stem-cell Transplantation

Share this content:
Administration of the anti-CTLA-4 antibody ipilimumab is feasible for patients with recurrent hematologic malignancies.
Administration of the anti-CTLA-4 antibody ipilimumab is feasible for patients with recurrent hematologic malignancies.

Despite the occurrence of immune-mediate toxic effects and graft-versus-host disease (GVHD), administration of the anti-cytotoxic T-lymphocyte–associated protein 4 (CTLA-4) antibody ipilimumab is feasible for patients with recurrent hematologic malignancies after undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT), according to a study published in The New England Journal of Medicine.

Because the loss of donor-mediated immune antitumor activity following allo-HSCT increases the risk of relapse of blood cancers, researchers assessed whether targeting CTLA-4 with ipilimumab could restore antitumor reactivity via a graft-versus-tumor effect.

For this multicenter, phase 1/1b study, investigators enrolled 28 patients with a relapsed hematologic malignancy after receiving allo-HSCT. All participants received induction therapy with ipilimumab at a dose of 3 or 10 mg/kg every 3 weeks for 4 doses. Patients who had achieved clinical benefit then received additional doses of ipilimumab every 12 weeks for up to 60 weeks.

RELATED: Papular, Nodular Eruptions Frequent With Anti-PD1/PD-L1 Therapy

Among the 22 patients who had received the 10-mg/kg ipilimumab dose, 23% had a complete response, 9% had a partial response, and 27% had decreased tumor burden. Four patients had a durable response for more than 1 year.

Of 28 patients, 21% experienced immune-related adverse events, including 1 death, and 14% reported GVHD that resulted in discontinuation of ipilimumab administration.                                       

Reference

  1. Davids MS, Kim HT, Bachireddy P, et al. Ipilimumab for patients with relapse after allogeneic transplantation. N Engl J Med. 2016;375:143-153.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters